Loading
Life sciences · Journal article
Journal of Nuclear Medicine · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Uterine serous carcinoma (USC) is an aggressive endometrial cancer frequently associated with human epidermal growth factor receptor type 2 (HER2) overexpression and poor prognosis. Although trastuzumab improves outcomes, resistance remains a major clinical problem. This study determined whether targeted α-therapy using 211At-labeled trastuzumab (211At-trastuzumab) can overcome trastuzumab resistance in HER2-positive USC. Methods:211At-trastuzumab was synthesized, and its binding and cytotoxicity in HER2-positive USC cell lines were evaluated. Three trastuzumab-resistant peritoneal metastasis mouse models were established: intrinsic resistance, trastuzumab-induced resistance, and acquired resistance. After a single intravenous administration (1.85 MBq), therapeutic efficacy was assessed using bioluminescence imaging and biodistribution analysis. Results:211At-trastuzumab showed specific binding to HER2-positive USC cells and significantly reduced cell viability relative to the controls. In vivo, tumor uptake reached 17.4 ± 1.9 %ID/g at 24 h. A single dose significantly suppressed tumor growth in all 3 resistant models: intrinsic, induced, and acquired resistance (P < 0.05 vs. controls). No severe toxicity was observed. Conclusion:211At-trastuzumab demonstrates potent antitumor efficacy against trastuzumab-resistant HER2-positive USC in preclinical models. Targeted α-therapy may represent a promising strategy to overcome resistance to HER2-targeted therapy.